Jane Street Group LLC Raises Position in Veracyte, Inc. (NASDAQ:VCYT)

Jane Street Group LLC grew its position in shares of Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 276.4% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 301,652 shares of the biotechnology company's stock after purchasing an additional 221,504 shares during the period. Jane Street Group LLC owned approximately 0.39% of Veracyte worth $10,268,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of VCYT. State Street Corp boosted its stake in shares of Veracyte by 0.3% in the third quarter. State Street Corp now owns 2,916,515 shares of the biotechnology company's stock valued at $99,278,000 after purchasing an additional 7,920 shares during the period. William Blair Investment Management LLC grew its stake in shares of Veracyte by 67.4% in the second quarter. William Blair Investment Management LLC now owns 1,241,671 shares of the biotechnology company's stock worth $26,907,000 after acquiring an additional 500,020 shares in the last quarter. Granite Investment Partners LLC increased its position in shares of Veracyte by 2.1% during the second quarter. Granite Investment Partners LLC now owns 934,994 shares of the biotechnology company's stock worth $20,261,000 after acquiring an additional 19,244 shares during the period. Eventide Asset Management LLC increased its position in shares of Veracyte by 20.2% during the third quarter. Eventide Asset Management LLC now owns 677,883 shares of the biotechnology company's stock worth $23,075,000 after acquiring an additional 113,883 shares during the period. Finally, Fiera Capital Corp raised its stake in shares of Veracyte by 1.2% in the second quarter. Fiera Capital Corp now owns 625,536 shares of the biotechnology company's stock valued at $13,555,000 after acquiring an additional 7,219 shares in the last quarter.

Veracyte Trading Down 2.0 %

Shares of NASDAQ VCYT traded down $0.88 during mid-day trading on Friday, reaching $43.52. The company had a trading volume of 202,748 shares, compared to its average volume of 768,457. Veracyte, Inc. has a 52-week low of $18.61 and a 52-week high of $46.00. The firm has a 50 day simple moving average of $37.50 and a two-hundred day simple moving average of $30.33.

Veracyte (NASDAQ:VCYT - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.16. Veracyte had a positive return on equity of 3.02% and a negative net margin of 2.18%. The company had revenue of $115.86 million for the quarter, compared to analyst estimates of $109.81 million. During the same quarter last year, the company posted ($0.03) earnings per share. The business's quarterly revenue was up 28.6% compared to the same quarter last year. On average, sell-side analysts expect that Veracyte, Inc. will post 0.38 earnings per share for the current fiscal year.

Insider Buying and Selling at Veracyte

In other Veracyte news, insider John Leite sold 1,050 shares of the company's stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $43.25, for a total transaction of $45,412.50. Following the completion of the sale, the insider now directly owns 73,810 shares of the company's stock, valued at $3,192,282.50. This represents a 1.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Jonathan Wygant sold 956 shares of Veracyte stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $43.36, for a total value of $41,452.16. Following the completion of the transaction, the chief accounting officer now owns 40,270 shares in the company, valued at $1,746,107.20. This trade represents a 2.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 19,211 shares of company stock worth $787,542. 1.30% of the stock is owned by insiders.

Analyst Ratings Changes

VCYT has been the topic of several recent research reports. Leerink Partners upped their price target on Veracyte from $35.00 to $40.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $37.00 target price (down previously from $38.00) on shares of Veracyte in a report on Thursday, December 5th. Scotiabank lifted their price target on shares of Veracyte from $40.00 to $44.00 and gave the stock a "sector outperform" rating in a research note on Friday, November 8th. Morgan Stanley increased their price objective on shares of Veracyte from $26.00 to $28.00 and gave the company an "underweight" rating in a research report on Monday, November 18th. Finally, UBS Group lifted their price objective on shares of Veracyte from $43.00 to $46.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $41.13.

Veracyte Company Profile

Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.